Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Tutte le Categorie
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Transaction in Own Shares
ENDEAVOUR ANNOUNCES TRANSACTION IN OWN SHARESLondon, 24 April 2024– Endeavour Mining plc (LSE:EDV, TSX:EDV) (“the Company”) announces it has purchased the following number of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited.Aggregated informationDates of purchase:23 April 2024Aggregate number of ordinary shares of USD 0.01 each purchased:29,500Lowest price paid per share (GBp): 1,646.00Highest price paid per share...
Nasdaq GlobeNewswire
24/04/2024
Ringkjøbing Landbobank's quarterly report for the first quarter of 2024
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders24 April 2024Ringkjøbing Landbobank's quarterly report for the first quarter of 2024The bank's board of directors and general management today approved the quarterly report for the first quarter of 2024. The bank delivers core earnings of DKK 793 million and net profit of DKK 616 million in the first quarter of the year. The net profit is equivalent to a 24% p.a. return on equity.Core earnings ...
Nasdaq GlobeNewswire
24/04/2024
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on…
Press ReleaseNicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of anad hocagentApril 24, 2024 – release at 07:30 CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been...
Nasdaq GlobeNewswire
24/04/2024
BGHL (GBP): NAV(s)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 23 Apr 2024.Estimated NAV Euro SharesSterling SharesEstimated NAV€ 27.8695£ 24.9583Estimated MTD return 1.15 % 1.25 %Estimated YTD return 1.17 % 1.58 %Estimated...
Nasdaq GlobeNewswire
24/04/2024
BGHL (EUR): NAV(s)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 23 Apr 2024.Estimated NAV Euro SharesSterling SharesEstimated NAV€ 27.8695£ 24.9583Estimated MTD return 1.15 % 1.25 %Estimated YTD return 1.17 % 1.58 %Estimated...
Nasdaq GlobeNewswire
24/04/2024
Q1 2024 results: KPN delivers solid start to the year
Continued Group service revenue growth (+3.6% y-on-y), mainly driven by Consumer (+4.5%) and Business (+3.2%)Ongoing positive net adds in Consumer postpaid +30k and broadband +13k, of which 8k related to Kabeltex acquisitionExpanded fiber footprint with +130k HP in Q1 2024 (+159k HP including Glaspoort)Adj. EBITDA AL of € 605m (+3.6% y-on-y), quarterly FCF generation impacted by intra-year phasingACM unconditionally approved Youfone acquisition, transaction closed…
Nasdaq GlobeNewswire
24/04/2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth…
PARIS, FRANCE, 24 April 2024- Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER 1Growth platforms 2 509.7452.012.8%16.2%New medicines 3 45.514.3n/an/aSomatuline ® 257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5% Total Sales822.4741.910.9%13...
Nasdaq GlobeNewswire
24/04/2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in…
Group salesgrew by 2% 1at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies,saleswere 6% lower when reported in CHF Pharmaceuticals Divisionbase business 2 grew by 7%, driven by strong sales of medicines to treat...
Nasdaq GlobeNewswire
24/04/2024
Norsk Hydro: Resilient in weak markets, positioned for growth
Hydro's adjusted EBITDA for the first quarter of 2024 was NOK 5,411 million, down from NOK 7,525 million for the same quarter last year. Lower aluminium sales prices, Extrusions volumes and recycling margins, and higher fixed costs negatively impacted results, partly offset by lower raw material costs. This resulted in an adjusted RoaCE of 5.6 percent over the last twelve months. Results down on weaker demand and recycling margins, revenue drivers increasingIncreasing recycling and...
Nasdaq GlobeNewswire
24/04/2024
Wereldhave Trading update Q1 2024
Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the...
Nasdaq GlobeNewswire
24/04/2024
TGS Q1 2024 Presentation and Webcast
OSLO, Norway(24 April 2024) - TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online.Access and registration for online attendees are available by copying and pasting this link into your browser: ...
Nasdaq GlobeNewswire
24/04/2024
First quarter 2024 financial information: Good start to the year
Good start to the year _PRESS RELEASE_ First quarter 2024 standard sales of €1,692 million, up +2.8% organically year-on-year and up +4.7% excluding Other activitiesElectrification businesses up +6.7% organically, reflecting double digit growth in Generation & Transmission segment and an acceleration in electrification trends globally Record adjusted backlog for Generation & Transmission, mainly subsea-driven, at €6.7 billion, up +10.2% compared to December 2023...
Nasdaq GlobeNewswire
24/04/2024
IMCD Spain expands its Pharmaceuticals presence with the acquisition of…
ROTTERDAM, The Netherlands 24 April 2024 –IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry. Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical...
Nasdaq GlobeNewswire
24/04/2024
WithSecure Interim report 1 January – 31 March 2024: Elements Company…
WithSecure Corporation, Interim report release 1 January – 31 March 2024, 24 April 2024 at 8.00 EEST WithSecure Interim report 1 January – 31 March 2024: Elements Company profitability developing positively, despite slow start of the yearHighlights of January – March 2024 (“first quarter”)Annual Recurring Revenue (ARR) (1) for Elements Cloud (2) increased by 10% to EUR 80.5 million (EUR 73.4 million)Elements Cloud ARR increase from previous quarter was 3%Net Revenue Retention...
Nasdaq GlobeNewswire
24/04/2024
BioSenic postpones its annual general meeting of the shareholders and provides…
PRESS RELEASE - PRIVILEGED INFORMATIONIn view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis....
Nasdaq GlobeNewswire
24/04/2024
Pharming to be honored as Industry Innovator at National Organization for Rare…
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterizedLeiden, the Netherlands, April 24, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare...
Nasdaq GlobeNewswire
24/04/2024
Reminder: Unifiedpost Group Strategy Update Presentation on 30 April 2024
The event will take place from 2:00pm to 4:00pm CET on Tuesday, 30 April 2024. The presenting team will be Hans Leybaert, CEO, Koen De Brabander, CFO, and some of the group's business leaders. The agenda for the day is as follows:IntroductionsKey objectivesBusiness updateStrategic initiativesFinancial reviewClosing remarksQ&AThe event will take place virtually and will be available to stream via a live webcast. To register your interest in the event,...
Nasdaq GlobeNewswire
24/04/2024
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter
Borregaard's operating revenues reached NOK 1,975 million (NOK 1,850 million) 2in the 1 stquarter of 2024. EBITDA 1increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1 stquarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood...
Nasdaq GlobeNewswire
24/04/2024
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides…
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant...
Nasdaq GlobeNewswire
24/04/2024
Jean-Michel Jarre is world's first passenger to take off in KleinVision's flying…
"It is like being in a Jules Verne book, but for real! One second you speak to the driver, and next, you are up there in the air – an amazing experience!" said Jean-Michel Jarre after completing two flights in the AirCar at Piestany international airport. "It is like being in aJules Vernebook, but for real! One second you speak to the driver, and next, you are up there in the air – an amazing experience!"saidJean-Michel Jarre after completing two flights in the AirCar at…
PR Newswire
24/04/2024
Vopak reports strong Q1 2024 results and increases FY 2024 outlook
The Netherlands, 24 April 2024 Vopak reports strong Q1 2024 results and increases FY 2024 outlookKey highlights Q1 2024ImproveIncreased net profit -including exceptional items 1 - in Q1 2024 to EUR 106 million, an improvement of 3% year-on-year, driven by favorable storage demand across different geographies and marketsIncreased proportional EBITDA -excluding exceptional items 1 - in Q1 2024 to EUR 298 million, an improvement of 9% year-on-year when adjusted for divestment...
Nasdaq GlobeNewswire
24/04/2024
Melexis Q1 2024 results – First quarter sales of 241.8 million EUR
Regulated information Intermediate declaration by the Board of DirectorsIeper, Belgium - April 24th, 2024, 07.00 hrs CET Dear,Please find herewith the link to our most recent press release: www.melexis.com/en/news/2024/financial/melexis-q1-2024-resultsAttachment PR_ENG_Melexis_Q1 2024
Nasdaq GlobeNewswire
24/04/2024
Clayfin Technologies and Jana Small Finance Bank Honored with Prestigious IBSi…
Nikhil Gokhale, Director - Research & Digital Properties at IBS Intelligence, extended congratulations to Jana Small Finance Bank and Clayfin for their achievement as the 'Regional Winners: Asia' at the Digital Banking Awards 2024. Clayfin's Omnichannel Digital Banking Solution at Jana SFB led to significant improvements in productivity, efficiency, and cost savings, highlighting their leadership in digital transformation. Nikhil Gokhale, Director - Research & Digital Properties at…
PR Newswire
24/04/2024
Novartis and Medicines for Malaria Venture announce positive efficacy and safety…
There is currently no evidence-based treatment for the smallest babies with malariaThe CALINA study tested a new ratio and dose of Coartem ®(artemether- lumefantrine) to account for metabolic differences in babies under 5 kgThe CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024– Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase...
Nasdaq GlobeNewswire
24/04/2024
Altri Comunicati